Evidence map›Paper›PMID 28901643›Full record

ReviewBritish journal of clinical pharmacology2018

Renal function monitoring in heart failure - what is the optimal frequency? A narrative review.

Ahmed Al-Naher, David Wright, Mark Alexander John Devonald, Munir Pirmohamed

Open access · hybridAbstract readReview
In one paragraph

Review in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ahmed Al-NaherThe Wolfson Centre for Personalised Medicine, The University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-7057-0437
David WrightInstitute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK.
Mark Alexander John DevonaldRenal and Transplant Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Munir PirmohamedThe Wolfson Centre for Personalised Medicine, The University of Liverpool, Liverpool, UK.
University of Liverpool · GBNottingham University Hospitals NHS Trust · GB

Funding

Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

The second most common cause of hospitalization due to adverse drug reactions in the UK is renal dysfunction due to diuretics, particularly in patients with heart failure, where diuretic therapy is a mainstay of treatment regimens. Therefore, the optimal frequency for monitoring renal function in these patients is an important consideration for preventing renal failure and hospitalization. This review looks at the current evidence for optimal monitoring practices of renal function in patients with heart failure according to national and international guidelines on the management of heart failure (AHA/NICE/ESC/SIGN). Current guidance of renal function monitoring is in large part based on expert opinion, with a lack of clinical studies that have specifically evaluated the optimal frequency of renal function monitoring in patients with heart failure. Furthermore, there is variability between guidelines, and recommendations are typically nonspecific. Safer prescribing of diuretics in combination with other antiheart failure treatments requires better evidence for frequency of renal function monitoring. We suggest developing more personalized monitoring rather than from the current medication-based guidance. Such flexible clinical guidelines could be implemented using intelligent clinical decision support systems. Personalized renal function monitoring would be more effective in preventing renal decline, rather than reacting to it.

Indexed as

Acute Kidney InjuryAngiotensin-Converting Enzyme InhibitorsBiomarkersDecision Support Systems, ClinicalDiureticsDrug Therapy, CombinationGlomerular Filtration RateHeart FailureHospitalizationHumansKidneyPractice Guidelines as TopicTime FactorsAngiotensin-Converting Enzyme InhibitorsBiomarkersDiureticsclinical decision systemsdiureticsdrug safetyheart failurekidney failurerenal function monitoring

Identifiers

PMID28901643
PMCPMC5736847
OpenAlexW2755317040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.